Compare PPTA & AMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PPTA | AMRX |
|---|---|---|
| Founded | 2011 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 4.0B |
| IPO Year | 2011 | 2018 |
| Metric | PPTA | AMRX |
|---|---|---|
| Price | $21.33 | $17.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $37.38 | $15.60 |
| AVG Volume (30 Days) | 2.1M | ★ 2.3M |
| Earning Date | 05-15-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 157.89 |
| EPS | N/A | ★ 0.19 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $4.48 |
| Revenue Next Year | N/A | $7.13 |
| P/E Ratio | ★ N/A | $90.32 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.21 | $7.67 |
| 52 Week High | $37.37 | $17.86 |
| Indicator | PPTA | AMRX |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 75.43 |
| Support Level | $20.74 | $12.46 |
| Resistance Level | $26.23 | N/A |
| Average True Range (ATR) | 1.30 | 0.55 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 20.25 | 66.67 |
Perpetua Resources Corp is engaged in acquiring mining properties with the intention of exploring, evaluating, developing and placing them into production, if warranted. Its principal mineral project is the Stibnite Gold Project in Idaho, USA, which contains several gold, silver and antimony mineral deposits. The company's current focus is to redevelop three of the Deposits known as the Hangar Flats Deposit, West End Deposit and Yellow Pine Deposit, all of which are located within the Stibnite Gold Project, as well as reprocess certain historical tailings located on the Project. It operates in one segment: mineral exploration and development in the United States.
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.